Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01020019 · ClinicalTrials.gov registry record · Phase 2
Combined Pharmacotherapy for Cannabis Dependency
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
NCT01020019 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 156 participants.
The verdict
NCT01020019, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
Study Summary
The purpose of this study is to see if Lofexidine in combination with Marinol is superior to placebo in achieving abstinence, reducing cannabis use and reducing withdrawal in cannabis-dependent patients seeking treatment for their marijuana use.
Interventions
- DRUG Placebo
- DRUG Dronabinol
- DRUG Lofexidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01020019
The ClinicalTrials.gov registry entry for NCT01020019 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01020019 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01020019 about?
NCT01020019 is a clinical study titled "Combined Pharmacotherapy for Cannabis Dependency". The purpose of this study is to see if Lofexidine in combination with Marinol is superior to placebo in achieving abstinence, reducing cannabis use and reducing withdrawal in cannabis-dependent patients seeking treatment for their marijuana use.
What is the current status of trial NCT01020019?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2010-01. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01020019?
The interventions under investigation include: Placebo (DRUG), Dronabinol (DRUG), Lofexidine (DRUG).
Who is sponsoring clinical trial NCT01020019?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.